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Most data for Central Nervous System Tuberculosis (CNS-TB) derive from high-
incidence, resource-limited countries. We sought to determine the presentation,
management and outcomes of CNS-TB in a low-incidence setting with accessible
healthcare.
Methods
We undertook a retrospective, observational study of CNS-TB in adults at a single
tertiary-referral London hospital (2001-2017). Cases were categorised as either TB
meningitis (TBM) or TB mass lesions without meningitis (TBML), applying novel criteria
for definite, probable, and possible TBML.
Results
We identified sixty-two cases of TBM (37% definite; 31% probable; 32% possible)
alongside 14 TBML cases (36% definite; 29% probable; and 36% possible). Clinical
presentation was highly variable. Among CSF parameters, hypoglycorrhachia proved
most discriminatory for “definite” TBM. Neurosurgical intervention was required for
mass-effect or hydrocephalus in 16%. Mortality was higher in TBM versus TBML (16%
vs 0%) but overall morbidity was significant; 35% of TBM and 28% of TBML survivors
suffered persisting neurological disability at 12-months. Hydrocephalus, infarct, basal
enhancement and low CSF white cell count were independently associated with worse
neurological outcomes.
Conclusion
Although mortality was lower than previously reported in other settings, morbidity was
significant, highlighting the need for improved CNS-TB diagnostics, therapeutics and
interventions to mitigate neurological sequelae.
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RESPONSE TO REVIEWERS COMMENTS 
We thank the reviewers for their time spent looking over our article and for their constructive 
comments which we believe have improved the quality of our manuscript.  
Please see below our point-by point responses (in blue text) to Reviewers’ comments and 
suggestions and how these have been addressed in the revision (new text in Italics).  




This is a retrospective case series evaluating TBM and TB mass lesions, the latter which the 
authors are proposing as an entity.  Descriptions are detailed, the paper well-written and the 
authors should be commended on the effort taken. 
Methods: 
1) ".. tuberculous mass lesion in the absence of meningitic clinical features". I would also add
absence of CSF features indicating meningitis, or something along those lines, as readers
would reflexively wonder whether CSF suggestive of meningitis are included.  This is a strength
of the paper, and can be further brought up.
We agree with this point and have clarified this further (see italics): 
Page 3:  The presence of radiological features consistent with a tuberculous mass lesion in the 
absence of meningitic clinical features and if performed, absence of inflammatory CSF, plus for: 
- ‘definite’ - microbiologic evidence of TB infection in CNS pus/tissue (culture, PCR-
positive or acid-fast bacilli (AFB) seen);
- ‘probable’ - evidence of extra-neural TB or granulomas (but not AFB-seen) on CNS
histology;
- ‘possible’ - the presence of radiological evidence alone in an appropriate clinical context.
3) "Outcomes are worse for TBM compared to those with mass lesions".  I would reserve this
statement, until the authors have made statistical correction for time to presentation, which I 
shall elaborate later. 
As this is not statistically significant (see change to text below) and time to presentation was not 
associated with worse outcomes we have removed this statement from the highlights.  
Pg 8 first para: "... TBML appeared to have a more benign course with 70% having a favourable 
outcome...".  This is not statistically significant, so the authors should phrase along the lines that 
there is "a trend towards a more benign course" and point out there it did not meet statistical 
significance in the text. 
We agree that this needed to be clearer. We have added a statistical comparison of death rates 
and have rephrased the text (page 8):  
For TBML, at 12-month follow-up, there were no deaths (p=0.19 versus TBM), but 4/14 (28%) 
suffered residual neurological disability (GOS 2-4). The rates of favourable outcome (GOS 5), 
70% for TBML and 56% for TBM, were not statistically different (p=0.37) but comparisons are 
difficult given the discrepant and small cohort sizes. Our data does however suggest that the 




- The authors reported statistical significance in the symptom duration prior to presentation
being longer in TBM compared to TBML (p=0.02). As a consequence, this may explain why the 
mortality and neurological morbidity may be more severe in the TBM group and should be 
adjusted for using a hypothetical cut off duration.  If after adjustment that TBM 
mortality/morbidity is higher, then would it be worth mentioning as one of the key features, and 
highlights of the paper. 
4) Univariable and multivariable analysis: Again should factor time to clinical presentation, since
TBM presented later than TBML which might affect neurological morbidity and mortality 
Table 5: 
1) Include time to clinical presentation and adjust
We thank the reviewer for highlighting this. Subsequently, we have analysed if longer duration 
of symptoms (>7 days vs ≤7 days) was associated with worse outcome (GOS 1-4) for the whole 
cohort (TBM and TBML). We found virtually identical outcomes (40% vs 37%, p=0.99) with no 
statistical difference.  
In order to enter into the multivariate analysis, a factor had to be significantly associated with 
TBM outcomes, not TBML outcomes given the small number of TBML cases. This did not apply 
to “time to presentation”. Even if we take significance for the whole cohort as a criterion for 
inclusion in the multivariate analysis, “time to presentation” does not merit inclusion (as above). 
We have therefore not included it in the multivariate analysis and have clarified the relationship 
between type of disease (TBML vs TBM) and outcomes in the text, as above 
Diagnostics - Neuroradiology 
1) ".. underwent neuro-imaging..." Are all these contrasted studies?  Because contrast would
help feature basal enhancement more prominently/ring enhancing lesions. 
Unfortunately, we do not have the data as to whether these were all contrast studies or not but 
that would be our normal practice.  
2) CSF findings - "...predominantly neutrophilic CSF in four patients". Are these
immunocompromised in anyway, eg HIV?  If so, this should be described in the text.  Severely 
immunocomp/low CD4 counts are often associated with predominant neutrophilic CSF in CNS-
TB patients.  
In line with this comment and a comment from reviewer number #2, we have now clarified this 
and changed the text:  
Page 6: Of the definite TBM cases, 4 (17%) immunocompetent patients had a neutrophilic 
pleocytosis, which is recognised in the early phase of TBM. One case had isolated 
hypoglycorrhachia only. 
Discussion: 
1) Page 11, first para: The authors postulated the pathophysiology behind the cellular response
with high CSF neutrophil counts and greater mortality.  Ong et al Journal of Neuroinflammation
2017 and Brilha et al Scientific Reports 2017 can be cited and commented on since neutrophils
can drive bloodbrain barrier disruption in TBM.
We appreciate the reviewer directing us to these interesting papers regarding how neutrophils 
contribute to CNS-TB immunopathology which are now referenced and briefly discussed, 
although not discussed in detail given word count limitations.  
Page 11: This observation is however consistent with data from large TBM cohorts in Vietnam 
where lower CSF lymphocyte counts predicted death regardless of HIV-status [31]. The type of 
cellular response may be critical as high CSF neutrophil counts appeared to predict greater 
mortality in an Indonesian TBM cohort [37], and studies have proposed neutrophils mediate 
disruption of the blood-brain-barrier and tissue destruction in CNS-TB [38, 39]. 
Table 3: 
1) CSF values: include neutrophil count, since the authors had commented in their Discussion
Neutrophil count is now included in Table 3. 
2) The authors might want to further clarify that these patients include the Confirmed, probable
and possible cases i:   In the rows, it would be devoting a section on how many of TBM, TBML 
are of each category. 
We tried to reformat and repopulate the Table in this way, but it resulted in a table that was too 
‘busy’, and very difficult to decipher so have not included this suggested revision.  
REVIEWER #2:    
This paper informs on clinical presentation and outcomes of CNS TB in a high resource setting. 
It is helpful in highlighting the variability of clinical presentation of such disease and the 
challenges posed by CNS TB diagnosis and management. Findings of substantial morbidity in 
CNS TB in high resource settings are in keeping with literature data (mostly arising from low 
resource settings) and therefore deemed to be of interest for publication.  Prognostic indicators 
of persistent morbidity are proposed, although validity of those can be affected by small sample 
size and suggest commenting in the limitations.  
 
We thank the reviewer for these comments and have expanded the study limitations to make 
this more explicit:  
 
Page 11: The study is limited by its single-centre, retrospective nature and small sample size, 
constraining statistical power; consequently, multivariable analysis results have large 
confidence intervals. Additionally, diagnostics and therapeutics have evolved during the 
timeframe of the study…. 
 
Overall the text is clear although the results section could be improved in writing, especially 
looking for simplification and avoidance of redundancies.  
In particular would suggest reviewing of:  
 
1) In the results section:  "Even in definite cases (Figure 2b), a number of individuals (5/23) 
had atypical patterns of CSF abnormalities, including a predominantly neutrophilic CSF in 
four patients (17%)." This statement is incorrect and should be rephrased as neutrophilic 
pleyocitosis is well described in TBM, especially in early phase of disease.  
 
We agree with this comment and also comment by reviewer no. 1 and have changed the text:  
Of the definite TBM cases, 4 (17%) immunocompetent patients had a neutrophilic pleocytosis, 
which is recognised in the early phase of TBM.  
 
2) In the Microbiology findings: 'Despite overlap, all three modalities, smear, culture and PCR, 
added additional cases to the total microbiologically-proven caseload.' Would suggest 
rephrasing as smear, culture and PCR are all indicated in the investigation of TBM, one test 
does not substitute the others. 
 
We agree with the reviewer and importance of this point. To simplify the results section, we 
have removed this sentence as it repeats itself in the discussion, and rephrased it as:  
 
‘Definite’ (microbiologically proven) diagnosis accounted for 37% of cases,  typifying the 
experience of other CNS-TB studies [20] and highlighting the limitations of the current 
diagnostic armamentarium of microscopy, culture and PCR. In this cohort, all three tests added 
to the microbiologically-proven cases. Hence, one diagnostic modality does not substitute for 
another; all are indicated in the investigation of TBM to maximise diagnostic yield. 
 
Re: Tables and Figures - would suggest the following  
Table 2 - to be reviewed- eg cough/weight loss/sweats could be listed perhaps clustered as 
systemic signs/extrapulmonary signs of disease 
 
We have simplified and now clustered weight loss and night sweats together.  
 
Figure 1 - would substitute legend A and B with TBM and TBML for simplification  
 
We have substituted A and B with TBM and TBML.  
 
Figure 2 - same as above and would remove figure 2 B as redundant 
 




REVIEWER #3:  
This manuscript describes a retrospective review of TB meningitis (N=62) and TB brain mass 
lesions without meningitis (n=14) in a single centre in London over 16 years (2001-2017). It's a 
nicely written report that describes the presentation, treatment and outcome of the cases, with 
some analysis of the features associated with poor outcome. There is very little to object to 
about the report, other than its obvious limitations of being relatively small (although not for the 
UK), retrospective, observational, and single centre. These limitations reduce the impact of the 
findings on clinical practice. But the data will be useful to those practicing in well-resourced 
settings and they highlight the devastating consequences of central nervous system 
tuberculosis regardless of available resources. 
 
We thank the reviewer for their positive comments; whilst we agree that this study will not 
change practice, it may help direct strategy. It is important to recognize that even in relatively 
well-resourced settings, outcomes remain poor and progress needs to be made to reduce the 
neurological burden on CNS-TB through the development of new therapeutic strategies. We 
also feel our paper makes a significant contribution to recognition of patterns of presentation of 
disease which have not been brought out in the same way in previous literature. 
Title: Presentations and Outcomes of Central Nervous System TB in a UK Cohort: The high 
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Most data for Central Nervous System Tuberculosis (CNS-TB) derive from high-incidence, 
resource-limited countries. We sought to determine the presentation, management and outcomes 
of CNS-TB in a low-incidence setting with accessible healthcare. 
Methods   
We undertook a retrospective, observational study of CNS-TB in adults at a single tertiary-referral 
London hospital (2001-2017). Cases were categorised as either TB meningitis (TBM) or TB mass 
lesions without meningitis (TBML), applying novel criteria for definite, probable, and possible 
TBML.  
Results 
We identified sixty-two cases of TBM (37% definite; 31% probable; 32% possible) alongside 14 
TBML cases (36% definite; 29% probable; and 36% possible). Clinical presentation was highly 
variable. Among CSF parameters, hypoglycorrhachia proved most discriminatory for “definite” 
TBM. Neurosurgical intervention was required for mass-effect or hydrocephalus in 16%. Mortality 
was higher in TBM versus TBML (16% vs 0%) but overall morbidity was significant; 35% of TBM 
and 28% of TBML survivors suffered persisting neurological disability at 12-months. In TBM, 
hydrocephalus, infarct, basal enhancement and low CSF white cell count were independently 
associated with worse neurological outcomes.  
Conclusion  
Although mortality was lower than previously reported in other settings, morbidity was significant, 
highlighting the need for improved CNS-TB diagnostics, therapeutics and interventions to mitigate 





























Clinical presentationSpectrum of disease
Number of symptoms
Graphical Abstract (for review)
HIGHLIGHTS:  
 Patterns of clinical presentation of TB meningitis are diverse  
 Diagnostic criteria for possible, probable & definite TB mass lesions are proposed 
 Seizures are a more frequent presentation in patients with TB mass lesions  





INTRODUCTION           
Central nervous system TB (CNS-TB) represents one of the most serious clinical manifestations 
of Mycobacterium tuberculosis (MTB) infection. There are two main patterns of disease 
presentation: (i) tuberculous meningitis (TBM) and (ii) intracranial tuberculous mass lesion(s) 
(TBML). Although CNS-TB only accounts for about 1% of TB cases [1], it contributes 
disproportionately to morbidity and mortality. Pathologically, CNS-TB arises from haematogenous 
seeding of M. tuberculosis to the brain following pulmonary infection. Small tuberculous foci (Rich 
foci) develop in the brain parenchyma or meninges [2]. Meningitis occurs when foci rupture into 
the subarachnoid space [3, 4]. Growth of the tubercules in the parenchyma generates mass 
lesions which may manifest as either solid, granulomatous lesions (tuberculoma) or, more rarely, 
as pus-filled cavities (tuberculous abscesses) [3]. Both processes may co-exist; mass lesions may 
occur in the absence of meningitis, and vice versa. 
 
Recognition and diagnosis of CNS-TB are difficult given the variability in clinical presentation. 
Although a scoring system of diagnostic criteria has been established for research studies [5], it 
is not generally used in clinical practice where heightened clinical suspicion and prompt 
recognition are the crucial factors determining early diagnosis, timely treatment and hence better 
outcomes.  Pathologically, the basal meninges are most affected. The consequent vasculitis of 
local and perforating blood vessels results in damage to cranial nerves, presenting as focal cranial 
neuropathies, and ischaemic parenchymal events. Obstruction to cerebrospinal fluid (CSF) flow 
is also common leading to hydrocephalus. Hence the importance of early diagnosis which creates 
a window of opportunity to treat before irreversible complications of hydrocephalus and/or 
ischaemic injury develop [6, 7]. Even with prompt treatment however, TBM is often a devastating 
disease; over half of patients die or suffer disabling neurological deficits [8–10]. Mortality is highest 
in those with HIV co-infection and in rifampicin-resistant or multi-drug resistant (MDR) TB [10]. 
Much less is known about TBML due to limited diagnostic criteria and the scarcity of outcome 
Manuscript Click here to view linked References
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data [11–14].   
 
To date, most data for CNS-TB originate from studies in high incidence, resource-limited 
countries. The emergent picture reflects these settings and may not be generalisable. We sought 
to address this knowledge gap by investigating the progress of a cohort of TBM/TBML patients in 
the UK. The UK is considered a low-incidence setting for TB (<10 per 100,000 overall, but ~19 
per 100,000 in London), with a low rate of HIV-TB co-infection (2.9% in 2018)[15], and a widely-
accessible healthcare system [16]. In London, CNS-TB represents ~5% of all TB infections [15]. 
Hence, we performed this review of all patients with CNS-TB at a London teaching hospital (with 
on-site infectious disease, intensive care, neurology and neurosurgical facilities) to determine the 






Case identification  
We performed a retrospective case-note review of adult patients (≥16 years) treated for CNS-TB 
at a single London tertiary referral centre between 2001-2017. Cases were identified from the 
London TB register and institutional records and designated as “TBM” or “TBML”. TBM cases 
were included if they met consensus case-definition diagnostic criteria [5] and sub-classified as 
‘definite’, ‘probable’ or ‘possible’ TBM on the basis of clinical features, CSF results, cerebral 
imaging and microbiology. Cases were excluded if TB treatment was discontinued in the context 
of an alternative diagnosis. To avoid duplication, cases with both a mass lesion and meningitis 
(either nuchal rigidity, inflammatory CSF or meningeal enhancement on imaging) were 
categorised as “TBM”; hence “TBML” in this context means a mass lesion without meningitis. 
Since ‘TBML without meningitis’ does not have a consensus case-definition, we developed novel 
criteria, defining TBML as: 
The presence of radiological features consistent with a tuberculous mass lesion in the absence 
of meningitic clinical features and, if performed, absence of inflammatory CSF, plus for:  
- ‘definite’ cases - microbiologic evidence of TB infection in CNS pus/tissue (culture, PCR-
positive or acid-fast bacilli (AFB) seen);  
- ‘probable’ cases - evidence of extra-neural TB or granuloma (but no AFB-seen) on CNS 
histology;  
- ‘possible’ cases - radiological evidence alone in an appropriate clinical context. 
 
Case note review  
Routinely-collected demographic, clinical, radiological, microbiological, and outcome data were 
documented. Disease severity on admission was graded according to British Medical Research 
(MRC) criteria: grade I, Glasgow Coma Score (GCS) of 15 with no focal neurology; grade II, GCS 
11-14, with or without focal neurological deficit or GCS of 15 with focal neurological deficit; grade 
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III, GCS ≤ 10, with or without focal neurological deficit [17]. Retrospective assessment of outcome 
was assessed from follow-up at ≥12-months using the Glasgow Outcome Score (GOS) [18], 
where 1 represents death; 2, vegetative state; 3, severely disabled (conscious but unable to live 
independently); 4, moderately disabled (able to live independently, but unable to return to work); 
5, no disability (resumed most normal activities). Deaths were included in all-cause mortality data 
if they occurred within the routine 12-month follow-up period. The study was registered and 
approved by the St Georges University Hospital Audit & Clinical Effectiveness Unit. UK National 
Research Ethics Service guidance permits retrospective evaluation of routinely-collected 
anonymised clinical data without formal ethics approval.  
 
Statistical analysis  
To compare clinical presentation and outcomes between TBM and TBML, univariable analysis of 
categorical data was performed using Chi-squared or Fishers exact test, and Student t-test or 
Mann-Whitney U test for continuous data. Receiver-operator characteristic (ROC) curves to 
identify which CSF parameters predicted a ‘definite’ case were generated using Prism (Graphpad 
software, Version 8). For TBM cases with 12-month follow-up, we performed a complete-case 
analysis using multivariable logistic regression to evaluate associations between an 
‘unfavourable’ outcome (GOS 1-4) and the following variables; age, MRC grade, HIV status, 
hydrocephalus, basal enhancement, presence of tuberculoma, cerebral infarct, CSF white cell 
count <50 cells/µL, CSF Protein ≥1g/L, and CSF glucose ≤2.2 mmol/L. Variables with a p-value 
≤0.10 in univariable analysis were included in a multivariable model. Multivariable logistic 
regression was performed using a backward stepwise elimination approach to construct the final 






Cohort characteristics  
The cohort comprised 76 cases with CNS-TB (Table 1), including 62 with TBM, of whom 37% 
(23/62) were classified as ‘definite’; 31% (19/62) ‘probable’; and 32% (20/62) ‘possible’, by 
consensus criteria [5]. The remaining 14 cases were defined as TBML (without meningitis), 
including 36% (5/14) ‘definite’; 29% (4/14) ‘probable’; and 36% (5/14) ‘possible’ cases, according 
to the criteria proposed above. The age range was wide, from 16 (minimum for inclusion) to 77 
years (median 38 years, IQR: 27-50). Both genders were equally represented (51% female). Most 
patients were born outside of the UK, but this was not a disease of new migrants; median time 
living in the UK prior to presentation was 10 years (IQR: 4-18 years). HIV co-infection was present 
in 26% (16/62) with TBM, but only 7% (1/14) of those with TBML (p=0.17). HIV-infected patients 
with CNS-TB tended to have advanced disease (median [range] CD4 cell count 81 [3-523] 
cells/uL) although CNS-TB also occurred in some patients with well-controlled HIV infection.  
 
Clinical presentation  
Clinical presentations of patients with CNS-TB were very diverse (Table 2).  For those with TBM, 
the most common features were fever, headache, and altered consciousness/confusion. The 
presentation of TBML was quite distinct; seizures were the commonest presentation (in 64% 
versus 18% in TBM; p=0.01) and represented the only symptom in a third of cases (36%, 5/14). 
Conversely, fever was significantly less common in TBML (14% (2/14) versus 68% (42/62) in 
TBM; p=0.01). Reported symptom duration prior to presentation was significantly longer in TBM 
compared to TBML (median 14 versus 3 days; p=0.02), primarily because half of TBML cases 
presented with seizure without preceding symptoms. Most TBM cases (52%, 32/62) presented 
without impaired consciousness or focal neurology (MRC grade I), whilst 44% (27/62) presented 
with grade II, and 5% (3/62) grade III disease.  
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Since clinicians recognise diseases by symptom-complexes, not isolated symptoms, we 
examined how symptoms clustered in TBM and TBML. Selecting the three most frequent 
symptoms in TBM (headache, fever, and altered consciousness/confusion, Table 2) plus 
seizures, the most frequent in TBML, we analysed by co-presentation (Figure 1). The triad of the 
three most common TBM symptoms presenting together was only seen in about a quarter of TBM 
cases (27%, 17/62); almost two-thirds (60%, 37/62) presented with only one or two of the triad, 
most commonly headache plus fever (25%, 16/62). TBML, by contrast, most frequently presented 
with the ‘seizure-only’ clinical phenotype. 
Diagnostics  
Neuroradiology 
All patients underwent neuro-imaging (CT 93%; MRI 90%; both CT & MRI 83%) (Table 3). In 
patients with TBM, basal enhancement was observed in 39% (24/62) and mass lesions were 
common (42%, 26/42). Hydrocephalus was found in 24% (15/62), more often in patients with 
MRC grade II or III disease (Hydrocephalus; MRC grade I: 9.3% (3/32) versus grade II/III: 40% 
(12/30), p=0.01). Cerebral infarction characterised 23% (14/62) of TBM cases. In TBML, 
conversely, hydrocephalus was only seen in 7% (1/14) and none had cerebral infarction. We 
reviewed the rate of resolution of mass lesions in all CNS-TB cases. 40 cases exhibited 
tuberculoma(s) on initial imaging (26/62 TBM plus 14/14 TBML); of these 22 (55%) had repeat 
imaging ≥ 9 months of follow-up. Tuberculoma(s) had resolved in 36% (8/22), were present but 
reduced in size in 41% (9/22), and had not changed in size in 23% (5/22).  
Highlighting the importance of looking for TB outside the CNS, radiological features suggestive of 
extra-neural TB were identified in a third of patients with CNS tuberculosis (TBM 34%, 21/62; 
TBML 36%, 5/14), including pulmonary disease (18%, 14/76), miliary TB (7%, 5/76); and disease 
at other sites (9%, 7/76; discitis/paraspinal mass, osteomyelitis, liver, spleen, and lymphadenitis). 
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The extra-neural site yielded a positive culture in 22% (17/76) of cases (10 sputum; 5 lymph node; 
1 pleural fluid; 1 liver biopsy, sputum & lymph node).  
 
CSF findings  
The classical triad of pleocytosis (with lymphocytic predominance), high protein and low glucose 
was the most commonly seen pattern of CSF abnormalities (Table 3 and Figure 2), but a third of 
patients (20/60) displayed alternative patterns. Of the definite TBM cases, 4 (17%) 
immunocompetent patients had a neutrophilic pleocytosis, which is recognised in the early phase 
of TBM. One case had isolated hypoglycorrhachia only. Notably, the absence of a raised CSF 
white cell count was not a rule-out (seen in 11 ‘all-TBM’ and 4 ‘definite-TBM’ cases). Assessing 
predictors of a ‘definite-TBM’ case by ROC analysis revealed that hypoglycorrhachia was the best 
discriminator (Figure 2). For TBML, CSF was obtained in four cases – all normal as per the TBML 
definition; in the remaining 10 cases, CSF examination was deemed clinically unnecessary or 
contraindicated.   
 
Microbiology findings  
TB was microbiologically confirmed in over a third of TBM cases (37%, 23/62). As expected, CSF 
direct smear examination was less sensitive than culture (AFB visualised in 11%, 7/61), although 
two cases on treatment at the time of LP were smear-positive but culture-negative. Cepheid 
Xpert® MTB/RIF PCR was introduced on-site in 2011; prior to this INNO-LiPA Rif.TB assay was 
performed by the TB Reference Laboratory.  PCR was positive in 20% (5/25) of the cases in 
whom it was performed including one culture-negative case. 57% (8/14) TBML cases had 
drainage or biopsy procedures. Diagnostic yield was high; two-thirds confirmed TB (4 culture-
positive; 1 AFB-seen) and 2 had histology consistent with TB (caseating/necrotising granuloma). 
Drug susceptibility testing of the cultured TB isolates (in TBM and TBML) demonstrated resistance 




Anti-tuberculosis chemotherapy for TBM and TBML closely followed contemporaneous 
local/national guidelines [4, 19], modified according to in vitro sensitivities. In the absence of 
known resistance, first-line therapy comprised ethambutol, isoniazid, rifampicin, and 
pyrazinamide (n=33) until 2008, when moxifloxacin largely replaced ethambutol (n=37). 8% (6/76) 
had alternative regimens due to drug-resistance or hepatic impairment. For both TBM and TBML, 
median (range) treatment duration was 12 (9–20) months (unascertained in 7 patients), being 
extended beyond 12 months in 11% (6/55) of TBM and 36% (5/14) of TBML cases for treatment 
interruptions or poor clinical response. Adjunctive steroid therapy was given in almost all cases 
(all CNS-TB, 95% 72/76; TBM 95%, 59/62; TBML 93%, 13/14).  
 
Overall, 16% (12/76) had at least one neurosurgical intervention for mass-effect or 
hydrocephalus, including four craniotomy and excision/drainage procedures, four external 
ventricular drains, four ventriculoperitoneal shunts, and one lumbar drain. In total, 56% (9/16) of 
patients with hydrocephalus underwent surgical management. A further five patients, had 
neurosurgical intervention for diagnostic purposes only.   
 
Clinical outcomes 
12-month outcome data was available for 90% (55/62) of TBM cases (7 transferred or lost to 
follow up) and all TBML cases (14/14) (Table 4). Mortality was significant; 16% (9/55) in the TBM 
group died within 1-year of diagnosis. Deaths occurred both early and late; the median (IQR) time 
from hospital admission to death was 74 (54 – 80) days. In survivors, neurological sequelae were 
common; 33% (15/46) were left with an intermediate or severe neurological disability (GOS 2-4). 
For TBML, at 12-month follow-up, there were no deaths (p=0.19 versus TBM), but 4/14 (28%) 
suffered residual neurological disability (GOS 2-4). The rates of favourable outcome (GOS 5), 
70% for TBML and 56% for TBM, were not statistically different (p=0.37), but comparisons are 
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difficult given the discrepant and small cohort sizes. Our data does however suggest that the 
hypothesis that TBML has a more benign course than TBM merits further exploration in larger 
adequately-powered studies.  
 
In terms of predictors of outcome from TBM, ten variables were identified in univariable analysis 
as significantly associated with ‘unfavourable’ outcome, defined as death or neurological disability 
[GOS ≤4] (Table 5).  Including variables with p ≤0.1 from the univariable analysis into a 
multivariable model, we identified hydrocephalus  (Odds Ratio [95% Confidence Interval], 23.03 
[2.92-181.35], p=0.01), cerebral infarct (OR 11.13 [1.36 – 91.94], p=0.03), basal enhancement 
(OR 5.66 [1.10-29.23], p=0.04), and a lower CSF WCC (OR 8.96 [1.51 – 53.16], p=0.02) as 





This retrospective review demonstrates the broad clinical spectrum of presentation of CNS-TB, 
the difficulties encountered in making a diagnosis and the frequency of complications, disability 
and mortality despite active management. This is the largest adult CNS-TB case series to date 
published in the UK and reveals some key insights.  
 
Firstly, it is clear that identification of CNS-TB remains extremely challenging for the clinician, 
especially when trying to use clinical features to differentiate it from other causes of 
meningoencephalitis and/or space-occupying lesions. No one symptom-complex identifies TBM. 
Although fever, headache and altered consciousness were common, as described previously [20–
24], ‘classical’ features such as neck stiffness were often absent. Indeed, analysing by symptom-
complex (Figure 1), patients frequently presented with just one or two major symptoms, 
underscoring the need for a high degree of diagnostic suspicion. Similarly, the time-scale of TBM 
cannot be relied upon to discriminate it from other meningeal diseases. Classically TBM is 
described as subacute with a non-specific prodrome but, in our series, extremes of presentation 
were also seen; approximately a quarter presented within a week of symptom-onset.   
 
Additionally, we have highlighted the contrasting presentations of TBM and TBML. TBML most 
commonly presents with isolated seizures, often without preceding symptoms or systemic 
features such as fever. Although headache and neurological manifestations were seen, 
depending on anatomic location, size and associated mass-effect, they were relatively 
uncommon. Importantly, the possibility that a space-occupying lesion might be TB should not be 
discounted because of the absence of systemic features. 
 
Secondly, we have shown how even with good laboratory support, diagnostic confirmation of 
CNS-TB remains difficult. ‘Definite’ (microbiologically proven) diagnosis accounted for 37% of 
11 
cases,  typifying the experience of other CNS-TB studies [20] and highlighting the limitations of 
the current diagnostic armamentarium of microscopy, culture and PCR. In this cohort, all three 
tests added to the microbiologically-proven cases. Hence, one diagnostic modality does not 
substitute for another; all are indicated in the investigation of TBM to maximise diagnostic yield. 
Measures to optimise diagnostic yield include using large volumes (>6ml) of CSF [25, 26], 
dedicating ≥20 minutes to microscopy [25], and centrifugation of CSF prior to PCR [27]. Cepheid 
Xpert®  MTB/Rif Ultra may enhance detection of TBM compared to Cepheid Xpert® or culture in 
patients with low bacillary loads [28] and in HIV-infected patients [29], but the improvement is 
modest, and the negative predictive value (~75-93% compared to probable or definite cases) 
insufficient to exclude TBM [30]. In TBML, diagnostic opportunities may be limited by the location 
of the lesion and surgical risks. Given such difficulties, searching for TB elsewhere can be very 
useful as demonstrated in this study where extra-neural TB was found in over a fifth (22%) of 
CNS-TB patients. 
Thirdly, we have demonstrated that even in relatively well-resourced healthcare settings with on-
site critical care and neurosurgery, TBM continues to cause significant mortality and long-term 
neurological morbidity. In this study about one sixth of patients died and over a third (33%) were 
left with neurological sequelae (GOS 2-4 at 12 months). Our mortality data is lower than some 
other settings [8, 20, 31]. Although partly attributable to the relatively low HIV prevalence in this 
cohort, we surmise from the relatively high proportion of patients presenting with MRC grade I 
disease that accessible healthcare [16] favours early presentation leading to improved survival. 
This data thus supports the drive to ensure rapidly accessible diagnostic and therapeutic facilities 
for management of CNS-TB. In contrast,  our morbidity data are comparable to other settings [8, 
10]; a significant proportion of patients were left with functional impairment, possibly because 





In terms of who suffered most morbidity, our finding in a multivariable model that individuals with 
hydrocephalus, cerebral infarction and basal enhancement are significantly more likely to have 
an ‘unfavourable’ outcome is consistent with previous literature [32–34]. Mitigating the impact of 
these adverse factors is one potential avenue to reduce neurological morbidity. Best practice for 
hydrocephalus management in CNS-TB remains unclear and differs between obstructive and 
communicating  hydrocephalus, the latter being more common in TBM [35]. Over half of those 
with hydrocephalus in this study underwent neurosurgical intervention demonstrating the value of 
co-location of neuroradiology and neurosurgical services with CNS-TB facilities. Cerebral 
infarction and basal enhancement reflect neuroinflammation characterised by cerebral vasculitis 
[3]. The high morbidity seen in this and other studies reflects the paucity of proven treatments for 
TBM-associated neuroinflammation. Corticosteroids are of proven benefit [8] but other adjunctive 
non-surgical therapies discussed in the literature such as aspirin, thalidomide, infliximab and 
interferon [35, 36] have not yet been sufficiently evaluated. In view of the adverse impact of 
neuroinflammation, it is perhaps surprising that we observed an apparently protective effect of 
high CSF white cell counts (≥50 cells/per µL) against ‘unfavourable’ outcomes. This observation 
is however consistent with data from large TBM cohorts in Vietnam where lower CSF lymphocyte 
counts predicted death regardless of HIV-status [31]. The type of cellular response may be critical 
as high CSF neutrophil counts appeared to predict greater mortality in an Indonesian TBM cohort 
[37], and studies have suggested neutrophils mediate disruption of the blood-brain-barrier and 
tissue destruction in CNS-TB [38, 39]. Other cohorts have found HIV to be associated with poor 
outcomes [10, 20]; the lack of association in this study is likely due to the low HIV prevalence and 
smaller cohort size. Better understanding of the relationship between host immune response and 





Finally, in terms of the discussion around optimal treatment regimens [40], this study does not 
add any comparative data as all patients received very similar treatment regimens, closely 
following national guidelines [4, 19], but it does provide some reflections on treatment duration. 
Almost all patients completed at least a year of anti-tuberculous chemotherapy but some were 
treated for longer, especially those with TBML, about 40% of whom were received extended 
therapy (>1 year). This almost certainly relates to the persistence of radiologic abnormalities: 64% 
of cases with tuberculoma who had subsequent imaging still had persisting radiologic 
abnormalities at ≥9 months follow-up. Previous studies have similarly shown visible tuberculomas 
on imaging in ~22-75% of patients after 9-18 months of therapy [13, 41–43]; indeed, one serial 
MRI study in TBM showed that ~70% of patients developed new tuberculomas during treatment 
and >50% who had ‘recovered’ at 9 months had persistent lesions on MRI [44], suggesting this 
may be part of the normal radio-pathological response to treated infection. Radiological resolution 
may therefore represent a poor index of ‘cure’ in such patients. 
 
The study is limited by its single-centre, retrospective nature and small sample size, constraining 
statistical power; consequently, multivariable analysis results have large confidence intervals. 
Additionally, diagnostics and therapeutics have evolved during the timeframe of the study. To 
avoid overinterpretation, we have restricted our conclusions to those validated by our own dataset 
and focussed on the generalisable clinical implications of our observations.  
 
CONCLUSION 
This case series highlights key practice points pivotal to prompt recognition, diagnosis and 
management of patients with CNS-TB. Even in relatively well-resourced settings with accessible 
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Table 1. Demographics, Diagnostic criteria and Severity of CNS-TB cases  
 




Tuberculous Mass Lesion 
(without meningitis) 
(n=14) 
Age median (range) years  
 
41 (16 – 77) 32 (19 - 60) 
Female sex, n (%)  
 
30 (48) 9 (64) 
Place of Birth, n (%) 
   Europe*  
   Africa  
   Asia 












HIV positive, n (%) 
   CD4 cells, median (range)   
 
16 (26) 
81 (3 – 523) 
1 (7) 
109 (NA) 
Definitiona, n (%) 
   Definite  
   Probable  










Admission MRC gradeb, n (%) 
   Grade I 
   Grade II  











Values are number (n) and percentage, except for age and CD4 where median (range) are shown. *All European 
cases were born in the UK, except for one. a Diagnostic categories according to consensus case definition for 
TBM (5) and criteria for TB Mass Lesions without meningitis defined in Methods. b Severity on admission was 
graded by Medical Research Council (MRC) criteria: Grade I indicates a Glasgow Coma Scale (GCS) of 15 with 
no neurological signs; Grade II, GCS 11-14, or 15 with focal neurological signs; Grade III, GCS of 10 or less. 















Fever (%)  44 (58) 42 (68) 2 (14) 0.01 
Headache (%)  48 (63) 41 (66) 7 (50) 0.36 
Confusion / Altered consciousness (%)  32 (42) 29 (47) 3 (21) 0.13 
Systemic symptoms (%)*  26 (34) 22 (35) 4 (29) 0.76 
Nausea/vomiting (%)  20 (26) 18 (29) 2 (14) 0.33 
Focal neurology (%)  22 (29) 18 (29) 4 (29) 0.99 
Cranial Nerve Palsy (%) 17 (22) 15 (24) 2 (14) 0.72 
Neck stiffness (%) 13 (17) 13 (21) 0 (0) 0.12 
Seizures (%)  20 (26) 11 (18) 9 (64) 0.01 
Cough (%) 12 (16) 11 (18) 1 (7) 0.45 
Duration of symptoms, days  14 (7-28) 14 (7-42) 3 (1-25) 0.02 
 
Frequencies of occurrence of each symptom ranked in descending order for TBM. Values are number (%) 
except for Duration which is median (IQR). P-values comparing TBM with TBML by Fishers-exact test.  
* Includes night sweats and weight loss.  Abbreviations: CNS-TB, Central nervous system tuberculosis; TBM, 
tuberculous meningitis; TBML, Tuberculous Mass Lesions without meningitis.  
  
Table 3. Radiological and Laboratory Findings in Tuberculous Meningitis (TBM) and Tuberculous Mass 
Lesions without meningitis (TBML) 




















Extra-neural TB, n (%) 
Radiological changes suggestive of 
extra-neural TB  
         Suggestive of pulmonary TB  
         Suggestive of miliary TB 
         Other  
 


















Laboratory values, median (IQR) 
   Serum CRP (mg/L)b 
   WCC (x109/L) 
 
 
10 (4 – 38) 
7 (6 – 9) 
 
9 (5 – 15) 
8 (6 – 8) 
CNS specimen results, n (%) 
Patients with LP performed  
Patients with tuberculoma pus/tissue 
taken 
 
CSF values, median (IQR) b 
   CSF total WCC (per µL) 
   CSF lymphocyte count (per µL) 
   CSF neutrophil count (per µL) 
   CSF protein (g/L)  
   CSF glucose (mmol/L)  








75 (21 – 178) 
60 (30 – 155) 
8 (2 - 28) 
1.5 (0.9 – 2.2) 
2.1 (1.2 – 2.8) 







3 (3 – 4) 
… 
… 
0.3 (0.2 – 0.4) 
3.3 (3.0 – 3.6) 
0.6 (0.6 – 0.7) 
CNS specimen microbiology , n (%)  
TB positivea CNS sample (CSF or 
tuberculoma tissue/pus) 
     
Drug susceptibilityc  n/N (%) 
    No resistance  
    INH monoresistance    
    MDR 



















a TB positive defined as either (1) positive CSF or tuberculoma tissue/pus culture for M. tuberculosis, (2) 
positive CSF or tuberculoma tissue/pus TB GeneXpert, or (3) AFB seen in CSF or tuberculoma tissue/pus. 
GeneXpert performed on 25/65 CSF samples, and 6/11 CNS tissue/pus samples; b Missing data: Serum CRP 
missing for 1 patient with TBM; CSF analysis; 1 patient had only CSF culture performed and missing 
WCC/lymphocyte/protein/glucose data; CSF/serum glucose ratio missing for 8 patients.  c INH monoresistance, 
resistance to INH but not rifampicin; MDR, resistance to at least isoniazid and rifampicin.  
Abbreviations: CNS, Central Nervous System; CRP, C reactive-protein; CSF, cerebrospinal fluid; INH, 
isoniazid; IQR, interquartile range; MDR, multi-drug resistant; n, number of patients; N, number of 
samples/investigations; TB, tuberculous; WCC, white cell count. 
Table 4. 12-month Outcomes in Tuberculous Meningitis (TBM) and Tuberculous Mass Lesions without 
meningitis (TBML) 
 










All CNS-TB 69 41 (59) 7 (10) 12 (17) 9 (13) 
TBM 55 31 (56) 6 (11) 9 (16) 9 (16) 
TBML 14 10 (70) 1 (7) 3 (21) 0 (0) 
 
*Number of patients with 12-month outcome data. CNS-TB, Central Nervous System TB; GOS, Glasgow 
Outcome Score (18); GOS 1 represents death; 2, vegetative state; 3, severely disabled (conscious but unable 
to live independently); 4, moderately disabled (able to live independently, but unable to return to work); 5, no 





Table 5. Univariable and Multivariable logistic regression analysis: Association between variables and an unfavourable outcome  



























1.02 (0.99 - 1.05) 
0.26   







1.60 (0.42 - 6.08) 
0.49   



















13.5 (2.61 - 68.88) 
0.01* 1 
23.0 (2.92 - 181.4) 
0.01 
 







8.1 (1.54 -42.48) 
0.02* 1 
11.1 (1.36 - 91.9) 
0.03 
 







3.71 (1.15 - 11.96) 
0.03* 1 
5.66 (1.10 - 29.2) 
0.04 
 







1.93 (0.64 - 5.80) 
0.24   







2.66 (0.83 - 8.57) 
0.10* 1 
8.96 (1.51 - 53.16) 
0.02 
 







0.53 (0.16 -1.73) 
0.24   










0.83 (0.28 - 2.48) 
0.75   
 
Complete case analysis – i.e. analysis included all subjects with no missing data, n=53. * Variables with a p-value ≤0.1 in univariable analysis were 
included in the multivariable analysis.  
Figure 1. Patterns of Clinical Presentation in Tuberculous Meningitis (TBM) and 
Tuberculous Mass Lesions without Meningitis (TBML) 
Patterns of clinical presentation in TBM (n= 62), and TBML (n=14). Histogram (i) demonstrates 
number of cases of presenting with combinations of headache (H), fever (F), altered 
consciousness (C), or seizure (S); Venn diagram (ii) shows number of cases with zero, one, two, 
three or four of these major symptoms.  
 
 
Figure 2.  Cerebrospinal Fluid (CSF) findings in Tuberculous Meningitis (TBM) 
(a) Patterns of CSF findings in all cases of TBM with CSF analysis results (n= 60), Histogram (i) 
demonstrates number of cases of TBM presenting with combinations of cell count ≥10 cells/ul, 
protein ≥ 0.45 g/L, CSF/serum glucose ratio ≤0.5 or CSF glucose ≤2.2; inset Venn diagram (ii) 
shows number of cases with zero, one, two, or three of these major CSF findings.  
(b) Receiver-operator characteristics for prediction of a “definite” case of TBM (versus possible or 
probable using definitions of Marais et al (5)) from protein (area under curve (AUC) 0.58, p=0.32), 
cell count (area 0.62, p=0.11), and glucose ratio (area 0.76, p=0.01). Maximizing Youden’s Index 
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